Trial Profile
A multi-center, open-label, observational study to evaluate the efficacy and safety of intravitreal injections (IVI) of Ranibizumab in patients with visual impairment due to Diabetic Macular Edema (DME) - UNVEIL- DME
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms UNVEIL- DME
- Sponsors Novartis Healthcare
- 22 May 2017 Status changed from recruiting to completed.
- 01 Sep 2016 New trial record